Clinical Trial Update: LYT-100 in Patients With BCRL [Phase 2]

View source ↗

Summary

Phase 2 trial of LYT-100 in breast cancer-related lymphedema was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer-related Lymphedema
• Lymphedema

Drugs mentioned

• LYT-100

Snippet

Sponsor: PureTech | Conditions: Breast Cancer Related Lymphoedema, Lymphoedema | Phase 2 | Status: TERMINATED | Results posted: 2024-04-23